Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Stopped early · Phase 2
Conditions studied: Leukemia
In brief
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with chronic phase chronic myelogenous leukemia.
Key facts
- Study ID
- NCT00428077
- Run by
- OHSU Knight Cancer Institute
- People needed
- 4
- Starts
- 2005-10-01
- Expected to finish
- 2009-04-01
- Last updated by the study team
- 2011-09-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- OHSU Knight Cancer Institute — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.